Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer

Abstract excerpt

BACKGROUND: mutation status is unknown. METHODS: mutation status. Patients were randomly assigned in a 2:1 ratio to receive olaparib tablets (300 mg twice daily) or placebo for up to 24 months; all the patients received bevacizumab at a dose of 15 mg per kilogram of body weight every 3 weeks for up to 15 months in total. The primary end point was the time from randomization until investigator-assessed disease...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Ovarian cancer diagnosis and treatment
• Share to PARP inhibition in cancer therapy
• Share to Toxin Mechanisms and Immunotoxins